Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many beta-lactamase enzymes, thereby extending its spectrum of activity.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Nosocomial pneumonia
* Febrile neutropenia (empiric treatment)
* Bacterial infections caused by susceptible Gram-positive and Gram-negative organisms, including *Pseudomonas aeruginosa*.
## Adult Dosing
The typical dose is 3.375 g (3 g piperacillin / 0.375 g tazobactam) or 4.5 g (4 g piperacillin / 0.5 g tazobactam) administered intravenously every 6 to 8 hours. Dosing frequency and duration depend on the severity of infection and clinical response. For serious infections, doses of 4.5 g every 6 hours are often used. For patients with *Pseudomonas aeruginosa* infections, doses up to 4.5 g every 6 hours are recommended. The maximum daily dose is generally considered 18 g.
## Pediatric Dosing
Dosing in pediatric patients varies significantly by age, weight, and indication. For children aged 2 months and older:
* **Intra-abdominal infections:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose administered intravenously every 8 hours.
* **Nosocomial pneumonia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose administered intravenously every 6 hours.
* **Febrile neutropenia:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose administered intravenously every 6 hours.
Maximum dose is typically 18 g/day for adolescents or as per package labeling. Specific dosing for neonates and infants younger than 2 months is not well established and should be based on institutional protocols and expert consultation.
## Dose Adjustments
* **Renal Impairment:** Dose reduction and/or adjustment of dosing interval is necessary in patients with a creatinine clearance (CrCl) less than 40 mL/min.
* CrCl 20-40 mL/min: 2.25 g (2 g piperacillin / 0.25 g tazobactam) or 3.375 g (3 g piperacillin / 0.375 g tazobactam) every 8 hours.
* CrCl < 20 mL/min: 2.25 g (2 g piperacillin / 0.25 g tazobactam) or 3.375 g (3 g piperacillin / 0.375 g tazobactam) every 12 hours.
* Dosing adjustments are based on the piperacillin component.
## Contraindications
* Known history of severe allergic reaction to penicillin, cephalosporins, beta-lactams, or other beta-lactamase inhibitors.
## Adverse Effects
* **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, fever.
* **Serious:** Hypersensitivity reactions (anaphylaxis), *Clostridioides difficile*-associated diarrhea, seizures (especially at high doses or in renal impairment), interstitial nephritis, hematologic abnormalities (neutropenia, thrombocytopenia, anemia), hepatotoxicity.
## Key Drug Interactions
* **Probenecid:** May increase piperacillin/tazobactam serum concentrations.
* **Aminoglycosides:** In vitro antagonism may occur with certain Gram-negative organisms; concurrent administration should be carefully considered based on susceptibility data and clinical indication.
* **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the effect of vecuronium. Monitor neuromuscular function.
* **Warfarin:** Piperacillin may decrease the effect of warfarin. Monitor INR closely.
## Monitoring
* Renal function (CrCl) for dose adjustments.
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of *C. difficile*-associated diarrhea.
* Complete blood count (CBC) with differential, particularly in prolonged therapy or high doses, to monitor for hematologic changes.
* Liver function tests (LFTs).
* Signs and symptoms of infection for therapeutic efficacy.
## Clinical Pearls
* Piperacillin/tazobactam is an excellent choice for empiric therapy in patients with suspected or documented infections due to multidrug-resistant Gram-negative organisms, including *Pseudomonas aeruginosa*.
* Dosing and duration of therapy should be guided by local antibiograms and clinical response.
* Administer intravenous infusions over at least 30 minutes to reduce the risk of infusion-related reactions. Avoid concurrent administration with aminoglycosides in the same IV line; flush the line between administrations.
* The presence of tazobactam does not increase the intrinsic activity of piperacillin against organisms resistant to piperacillin alone due to mechanisms other than beta-lactamase production.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant literature for complete details before making treatment decisions.*
